Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

The onset of psoriasis during the treatment of inflammatory bowel diseases with infliximab: should biological therapy be suspended?

Denadai R, Teixeira FV, Saad-Hossne R.

Arq Gastroenterol. 2012 Apr-Jun;49(2):172-6. Review.

2.

Induction or exacerbation of psoriatic lesions during anti-TNF-α therapy for inflammatory bowel disease: a systematic literature review based on 222 cases.

Denadai R, Teixeira FV, Steinwurz F, Romiti R, Saad-Hossne R.

J Crohns Colitis. 2013 Aug;7(7):517-24. doi: 10.1016/j.crohns.2012.08.007. Epub 2012 Sep 7. Review.

3.

Cutaneous adverse reaction to infliximab: report of psoriasis developing in 3 patients.

Severs GA, Lawlor TH, Purcell SM, Adler DJ, Thompson R.

Cutis. 2007 Sep;80(3):231-7.

PMID:
17956013
4.

Review article: anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease.

Fiorino G, Allez M, Malesci A, Danese S.

Aliment Pharmacol Ther. 2009 May 1;29(9):921-7. doi: 10.1111/j.1365-2036.2009.03955.x. Epub 2009 Feb 10. Review.

5.

Infliximab-induced psoriasis in children with inflammatory bowel disease.

Hiremath G, Duffy L, Leibowitz I.

J Pediatr Gastroenterol Nutr. 2011 Feb;52(2):230-2. doi: 10.1097/MPG.0b013e3181f3d9ab.

PMID:
21240020
6.

Cutaneous manifestations in inflammatory bowel diseases: eight cases of psoriasis induced by anti-tumor-necrosis-factor antibody therapy.

Passarini B, Infusino SD, Barbieri E, Varotti E, Gionchetti P, Rizzello F, Morselli C, Tambasco R, Campieri M.

Dermatology. 2007;215(4):295-300.

PMID:
17911986
7.

Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: a report of 21 cases.

Guerra I, Algaba A, Pérez-Calle JL, Chaparro M, Marín-Jiménez I, García-Castellanos R, González-Lama Y, López-Sanromán A, Manceñido N, Martínez-Montiel P, Quintanilla E, Taxonera C, Villafruela M, Romero-Maté A, López-Serrano P, Gisbert JP, Bermejo F.

J Crohns Colitis. 2012 Jun;6(5):518-23. doi: 10.1016/j.crohns.2011.10.007. Epub 2011 Nov 13.

PMID:
22398059
8.

Pustular psoriasis induced by infliximab.

Thurber M, Feasel A, Stroehlein J, Hymes SR.

J Drugs Dermatol. 2004 Jul-Aug;3(4):439-40.

PMID:
15303790
9.

[Psoriasis induced by infliximab].

Fernandes IC, Torres T, Sanches M, Velho G, Lago P, Selores M.

Acta Med Port. 2011 Dec;24 Suppl 3:709-12. Epub 2011 Dec 31. Portuguese.

10.
11.

Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.

Caprilli R, Angelucci E, Cocco A, Viscido A, Annese V, Ardizzone S, Biancone L, Castiglione F, Cottone M, Meucci G, Paoluzi P, Papi C, Sturniolo GC, Vecchi M.

Dig Liver Dis. 2005 Jun;37(6):407-17. Review.

PMID:
15893279
12.

Association Between Infliximab Trough Levels and the Occurrence of Paradoxical Manifestations in Patients with Inflammatory Bowel Disease: a Case-Control Study.

Coutzac C, Chapuis J, Poullenot F, Chabrun E, Capdepont M, Blanco P, Laharie D.

J Crohns Colitis. 2015 Nov;9(11):982-7. doi: 10.1093/ecco-jcc/jjv159. Epub 2015 Sep 7.

PMID:
26351388
13.

Infliximab safety profile and long-term applicability in inflammatory bowel disease: 9-year experience in clinical practice.

Zabana Y, Domènech E, Mañosa M, Garcia-Planella E, Bernal I, Cabré E, Gassull MA.

Aliment Pharmacol Ther. 2010 Mar;31(5):553-60. doi: 10.1111/j.1365-2036.2009.04206.x. Epub 2009 Nov 30.

14.

The safety and efficacy of antitumour necrosis factor-alpha therapy for inflammatory bowel disease in patients post liver transplantation: a case series.

Sandhu A, Alameel T, Dale CH, Levstik M, Chande N.

Aliment Pharmacol Ther. 2012 Jul;36(2):159-65. doi: 10.1111/j.1365-2036.2012.05141.x. Epub 2012 May 23.

15.

Careful patient selection may improve response rates to infliximab in inflammatory bowel disease.

Pearce CB, Lawrance IC.

J Gastroenterol Hepatol. 2007 Oct;22(10):1671-7.

PMID:
17845695
16.

[Infliximab in inflammatory bowel diseases--conference summary and suggested guidelines].

Dotan I, Chowers Y, Rachmilewitz D, Chermesh I, Lavy A, Israeli E, Karban A, Schwaber MJ, Odes S, Eliakim R.

Harefuah. 2006 Nov;145(11):844-9, 860. Hebrew.

PMID:
17183961
17.

Safety of infliximab treatment in pediatric patients with inflammatory bowel disease.

Friesen CA, Calabro C, Christenson K, Carpenter E, Welchert E, Daniel JF, Haslag S, Roberts CC.

J Pediatr Gastroenterol Nutr. 2004 Sep;39(3):265-9.

PMID:
15319627
18.

Paradoxical reactions induced by tumor necrosis factor-alpha antagonists: A literature review based on 46 cases.

Olteanu R, Zota A.

Indian J Dermatol Venereol Leprol. 2016 Jan-Feb;82(1):7-12. doi: 10.4103/0378-6323.172898. Review.

19.

Skin reactions during anti-TNFα therapy for pediatric inflammatory bowel disease: a 2-year prospective study.

Mälkönen T, Wikström A, Heiskanen K, Merras-Salmio L, Mustonen H, Sipponen T, Kolho KL.

Inflamm Bowel Dis. 2014 Aug;20(8):1309-15. doi: 10.1097/MIB.0000000000000088.

PMID:
24918318
20.

Psoriasiform and pustular eruption induced by infliximab.

Takahashi H, Hashimoto Y, Ishida-Yamamoto A, Ashida T, Kohgo Y, Iizuka H.

J Dermatol. 2007 Jul;34(7):468-72.

PMID:
17584325

Supplemental Content

Support Center